Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection

Journal of Medicinal Chemistry

Volumn 61, Issue 7, 2018, Pages 2636-2651

  Degoey, David A ^a   Chen, Hui Ju ^a   Cox, Philip B ^a   Wendt, Michael D ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERITINIB; COBIMETINIB; DACLATASVIR; EDOXABAN; ELBASVIR; GRAZOPREVIR; HEPACIVIRIN INHIBITOR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PROTEIN BCL 2; PROTEIN INHIBITOR; VELPATASVIR; VENETOCLAX;

COMPUTER MODEL; DATA BASE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHYSICAL CHEMISTRY; REVIEW; ALGORITHM; ANIMAL; BIOAVAILABILITY; DRUG DEVELOPMENT; MEDICINAL CHEMISTRY; TRENDS;

ALGORITHMS; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS;

EID: 85044421709     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00717     Document Type: Review

References (63)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25, 10.1016/S0169-409X(96)00423-1
2. Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 2014, 21, 1115-1142, 10.1016/j.chembiol.2014.08.013
3. Doak, B. C.; Zheng, J.; Dobritzsch, D.; Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 2016, 59, 2312-2327, 10.1021/acs.jmedchem.5b01286
4. Krämer, S. D.; Aschmann, H. E.; Hatibovic, M.; Hermann, K. F.; Neuhaus, C. S.; Brunner, C.; Belli, S. When barriers ignore the "rule-of-five". Adv. Drug Delivery Rev. 2016, 101, 62-74, 10.1016/j.addr.2016.02.001
5. Leeson, P. D. Molecular inflation, attrition and the rule of five. Adv. Drug Delivery Rev. 2016, 101, 22-33, 10.1016/j.addr.2016.01.018
6. Matsson, P.; Doak, B. C.; Over, B.; Kihlberg, J. Cell permeability beyond the rule of 5. Adv. Drug Delivery Rev. 2016, 101, 42-61, 10.1016/j.addr.2016.03.013
7. Pye, C. R.; Hewitt, W. M.; Schwochert, J. A.; Haddad, T. D.; Townsend, C. E.; Etienne, L.; Lao, Y.; Limberakis, C.; Furukawa, A.; Mathiowetz, A. M.; Price, D. A.; Liras, S.; Lokey, S. Non-classical size dependence of permeation defines bounds for passive adsorption of large drug molecules. J. Med. Chem. 2017, 60, 1665-1672, 10.1021/acs.jmedchem.6b01483
8. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J. Med. Chem. 2014, 57, 278-295, 10.1021/jm400887j
9. Villar, E. A.; Beglov, D.; Chennamadhavuni, S.; Porco, J. A.; Kozakov, D.; Vajda, S.; Whitty, A. How proteins bind macrocycles. Nat. Chem. Biol. 2014, 10, 723-731, 10.1038/nchembio.1584
10. Over, B.; Matsson, P.; Tyrchan, C.; Artursson, P.; Doak, B. C.; Foley, M. A.; Hilgendorf, C.; Johnston, S. E.; Lee, M. D.; Lewis, R. J.; McCarren, P.; Muncipinto, G.; Norinder, U.; Perry, M. W. D.; Duvall, J. R.; Kihlberg, J. Structural and conformational determinants of macrocycle cell permeability. Nat. Chem. Biol. 2016, 12, 1065-1074, 10.1038/nchembio.2203
11. Rezai, T.; Yu, B.; Millhauser, G. L.; Jacobson, M. P.; Lokey, R. S. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 2006, 128, 2510-2511, 10.1021/ja0563455
12. Hewitt, W. M.; Leung, S. S.; Pye, C. R.; Ponkey, A. R.; Bednarek, M.; Jacobson, M. P.; Lokey, R. S. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 2015, 137, 715-721, 10.1021/ja508766b
13. Nielsen, D. S.; Hoang, H. N.; Lohman, R. J.; Hill, T. A.; Lucke, A. J.; Craik, D. J.; Edmonds, D. J.; Griffith, D. A.; Rotter, C. J.; Ruggeri, R. B.; Price, D. A.; Liras, S.; Fairlie, D. P. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem., Int. Ed. 2014, 53, 12059-12063, 10.1002/anie.201405364
14. Wang, C. K.; Northfield, S. E.; Colless, B.; Chaousis, S.; Hamernig, I.; Lohman, R. J.; Nielsen, D. S.; Schroeder, C. I.; Liras, S.; Price, D. A.; Fairlie, D. P.; Craik, D. J. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 17504-17509, 10.1073/pnas.1417611111
15. Meanwell, N. A. Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space. Chem. Res. Toxicol. 2016, 29, 564-616, 10.1021/acs.chemrestox.6b00043
16. Leeson, P.; Davis, A. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47, 6338-6348, 10.1021/jm049717d
17. Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What do medicinal chemists actually make? A 50-year retrospective. J. Med. Chem. 2011, 54, 6405-6416, 10.1021/jm200504p
18. Leeson, P. D.; St-Gallay, S. A. The influence of the 'organizational factor' on compound quality in drug discovery. Nat. Rev. Drug Discovery 2011, 10, 749-765, 10.1038/nrd3552
19. Schneider, N.; Lowe, D. M.; Sayle, R. A.; Tarselli, M. A.; Landrum, G. A. Big data from pharmaceutical patents: a computational analysis of medicinal chemists' bread and butter. J. Med. Chem. 2016, 59, 4385-4402, 10.1021/acs.jmedchem.6b00153
20. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623, 10.1021/jm020017n
21. Young, R. J.; Green, D. V.; Luscombe, C. N.; Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today 2011, 16, 822-830, 10.1016/j.drudis.2011.06.001
22. Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. Increasing small molecule drug developability in sub-optimal chemical space. MedChemComm 2013, 4, 673-680, 10.1039/c3md00003f
23. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs. Nat. Chem. 2012, 4, 90-98, 10.1038/nchem.1243
24. Cox, P. B.; Gregg, R. J.; Vasudevan, A. Abbott physicochemical tiering (APT)-a unified approach to HTS triage. Bioorg. Med. Chem. 2012, 20, 4564-4573, 10.1016/j.bmc.2012.05.047
25. Tanaka, Y.; Kitamura, Y.; Maeda, K.; Sugiyama, Y. Explication of definitional description and empirical use of fraction of orally administered drugs absorbed from the intestine (Fa) and intestinal availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. J. Pharm. Sci. 2016, 105, 431-442, 10.1016/j.xphs.2015.11.005
26. Burton, P. S.; Goodwin, J. T.; Vidmar, T. J.; Amore, B. M. Predicting drug absorption: how nature made it a difficult problem. J. Pharmacol. Exp. Ther. 2002, 303, 889-895, 10.1124/jpet.102.035006
27. Tamai, I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Delivery Rev. 2012, 64, 508-514, 10.1016/j.addr.2011.07.007
28. Durmus, S.; van Hoppe, S.; Schinkel, A. H. The impact of organic anion-transporting polypeptides (OATPs) on disposition and toxicity of antitumor drugs: insights from knockout and humanized mice. Drug Resist. Updates 2016, 27, 72-88, 10.1016/j.drup.2016.06.005
29. Whitty, A.; Zhong, M.; Viarengo, L.; Beglov, D.; Hall, D. R.; Vajda, S. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discovery Today 2016, 21, 712-717, 10.1016/j.drudis.2016.02.005
30. Matsson, P.; Kihlberg, J. How big is too big for cell permeability?. J. Med. Chem. 2017, 60, 1662-1664, 10.1021/acs.jmedchem.7b00237
31. Caron, G.; Ermondi, G. Updating molecular properties during early drug discovery. Drug Discovery Today 2017, 22, 835-840, 10.1016/j.drudis.2016.11.017
32. Firth, N. C.; Brown, N.; Blagg, J. Plane of best fit: A novel method to characterize the three-dimensionality of molecules. J. Chem. Inf. Model. 2012, 52, 2516-2525, 10.1021/ci300293f
33. Guimaraes, C. R. W.; Mathiowetz, A. M.; Shalaeva, M.; Goetz, G.; Liras, S. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model. 2012, 52, 882-890, 10.1021/ci300010y
34. Belema, M.; Lopez, O. D.; Bender, J. A.; Romine, J. L.; St. Laurent, D. R.; Langley, D. R.; Lemm, J. A.; O'Boyle, D. R., II; Sun, J. H.; Wang, C.; Fridell, R. A.; Meanwell, N. A. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J. Med. Chem. 2014, 57, 1643-1672, 10.1021/jm401793m
35. DeGoey, D. A.; Betebenner, D. A.; Grampovnik, D. J.; Liu, D.; Pratt, J. K.; Tufano, M. D.; He, W.; Krishnan, P.; Pilot-Matias, T. J.; Marsh, K. C.; Molla, A.; Kempf, D. J.; Maring, C. J. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A. Bioorg. Med. Chem. Lett. 2013, 23, 3627-3630, 10.1016/j.bmcl.2013.04.009
36. Tellinghuisen, T. L.; Marcotrigiano, J.; Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005, 435, 374-379, 10.1038/nature03580
37. Love, R. A.; Brodsky, O.; Hickey, M. J.; Wells, P. A.; Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 2009, 83, 4395-4403, 10.1128/JVI.02352-08
38. O'Boyle, D. R., II; Sun, J.-H.; Nower, P. T.; Lemm, J. A.; Fridell, R. A.; Wang, C.; Romine, J. L.; Belema, M.; Nguyen, V. N.; St. Laurent, D. R.; Serrano-Wu, M.; Snyder, L. B.; Meanwell, N. A.; Langley, D. R.; Gao, M. Characterizations of HCV NS5A replication complex inhibitors. Virology 2013, 444, 343-354, 10.1016/j.virol.2013.06.032
39. Ascher, D. B.; Wielens, J.; Nero, T. L.; Doughty, L.; Morton, C. J.; Parker, M. W. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci. Rep. 2015, 4, 4765, 10.1038/srep04765
40. Belema, M.; Meanwell, N. A. Discovery of daclatasvir, a pangenotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J. Med. Chem. 2014, 57, 5057-5071, 10.1021/jm500335h
41. DeGoey, D. A.; Randolph, J. T.; Liu, D.; Pratt, J.; Hutchins, C.; Donner, P.; Krueger, A. C.; Matulenko, M.; Patel, S.; Motter, C. E.; Nelson, L.; Keddy, R.; Tufano, M.; Caspi, D. D.; Krishnan, P.; Mistry, N.; Koev, G.; Reisch, T. J.; Mondal, R.; Pilot-Matias, T.; Gao, Y.; Beno, D. W. A.; Maring, C. J.; Molla, A.; Dumas, E.; Campbell, A.; Williams, L.; Collins, C.; Wagner, R.; Kati, W. M. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J. Med. Chem. 2014, 57, 2047-2057, 10.1021/jm401398x
42. Hickman, D.; Vasavanonda, S.; Nequist, G.; Colletti, L.; Kati, W. M.; Bertz, R.; Hsu, A.; Kempf, D. J. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob. Agents Chemother. 2004, 48, 2911-2917, 10.1128/AAC.48.8.2911-2917.2004
43. Chang, W.; Mosley, R. T.; Bansal, S.; Keilman, M.; Lam, A. M.; Furman, P. A.; Otto, M. J.; Sofia, M. J. Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics. Bioorg. Med. Chem. Lett. 2012, 22, 2938, 10.1016/j.bmcl.2012.02.051
44. Wakenhut, F.; Tran, T. D.; Pickford, C.; Shaw, S.; Westby, M.; Smith-Burchnell, C.; Watson, L.; Paradowski, M.; Milbank, J.; Stonehouse, D.; Cheung, K.; Wybrow, R.; Daverio, F.; Crook, S.; Statham, K.; Leese, D.; Stead, D.; Adam, F.; Hay, D.; Roberts, L. R.; Chiva, J.-Y.; Nichols, C.; Blakemore, D. C.; Goetz, G. H.; Che, Y.; Gardner, I.; Dayal, S.; Pike, A.; Webster, R.; Pryde, D. C. The discovery of potent NS5A inhibitors with a unique resistance profile-part 2. ChemMedChem 2014, 9, 1387-1396, 10.1002/cmdc.201400046
45. Goetz, G. H.; Farrell, W.; Shalaeva, M.; Sciabola, S.; Anderson, D.; Yan, J.; Philippe, L.; Shapiro, M. J. High throughput method for the indirect detection of intramolecular hydrogen bonding. J. Med. Chem. 2014, 57, 2920-2929, 10.1021/jm401859b
46. Goetz, G. H.; Philippe, L.; Shapiro, M. J. EPSA: A novel supercritical fluid chromatography technique enabling the design of permeable cyclic peptides. ACS Med. Chem. Lett. 2014, 5, 1167-1172, 10.1021/ml500239m
47. Goetz, G. H.; Shalaeva, M.; Caron, G.; Ermondi, G.; Philippe, L. Relationship between passive permeability and molecular polarity using block relevance analysis. Mol. Pharmaceutics 2017, 14, 386-393, 10.1021/acs.molpharmaceut.6b00724
48. El Kassas, M.; Elbaz, T.; Hafez, E.; Esmat, G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin. Drug Saf. 2016, 15, 1643-1652, 10.1080/14740338.2017.1240781
49. Banerjee, D.; Reddy, K. R. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment. Pharmacol. Ther. 2016, 43, 674-696, 10.1111/apt.13514
50. Lucejko, M.; Parfieniuk-Kowerda, A.; Flisiak, R. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin. Pharmacother. 2016, 17, 1153-1164, 10.1080/14656566.2016.1176143
51. Smith, M. A.; Love, B. L.; Mohammad, R. A. The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy. Expert Opin. Drug Saf. 2015, 14, 1649-1652, 10.1517/14740338.2015.1088002
52. Pilot-Matias, T.; Tripathi, R.; Cohen, D.; Gaultier, I.; Dekhtyar, T.; Lu, L.; Reisch, T.; Irvin, M.; Hopkins, T.; Pithawalla, R.; Middleton, T.; Ng, T.; McDaniel, K.; Or, Y. S.; Menon, R.; Kempf, D.; Molla, A.; Collins, C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob. Agents Chemother. 2015, 59, 988-997, 10.1128/AAC.04227-14
53. Lawitz, E. J.; O'Riordan, W. D.; Asatryan, A.; Freilich, B. L.; Box, T. D.; Overcash, J. S.; Lovell, S.; Ng, T. I.; Liu, W.; Campbell, A.; Lin, C.-W.; Yao, B.; Kort, J. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob. Agents Chemother. 2016, 60, 1546-1555, 10.1128/AAC.02264-15
54. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.-C.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl family proteins induces regression of solid tumours. Nature 2005, 435, 677-681, 10.1038/nature03579
55. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S.-C.; Nimmer, P. M.; Oltersdorf, T.; Park, C.-M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 2007, 50, 641-662, 10.1021/jm061152t
56. Park, C.-M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 2008, 51, 6902-6915, 10.1021/jm800669s
57. Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discovery 2015, 14, 475-486, 10.1038/nrd4609
58. Wendt, M. D. The Discovery of Navitoclax, a Bcl-2 Family Iinhibitor. In Protein-Protein Interactions; Wendt, M. D., Ed.; Springer: Berlin, 2012; pp 231-258, DOI: 10.1007/978-3-642-28965-1-7.
59. Xiong, H.; Pradhan, R. S.; Nada, A.; Krivoshik, A. P.; Holen, K. D.; Rhodes, J. W.; Gordon, G. B.; Humerickhouse, R.; Awni, W. M. Studying navitoclax, a targeted anticancer drug, in healthy volunteers - ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014, 34, 3739-3746
60. Leverson, J. D.; Phillips, D. C.; Mitten, M. J.; Boghaert, E. R.; Diaz, D.; Tahir, S. K.; Belmont, L. D.; Nimmer, P.; Xiao, Y.; Ma, X. M.; Lowes, K. N.; Kovar, P.; Chen, J.; Jin, S.; Smith, M.; Xue, J.; Zhang, H.; Oleksijew, A.; Magoc, T. J.; Vaidya, K. S.; Albert, D. H.; Tarrant, J. M.; La, N.; Wang, L.; Tao, Z.-F.; Wendt, M. D.; Sampath, D.; Rosenberg, S. H.; Tse, C.; Huang, D. C. S.; Fairbrother, W. J.; Elmore, S. W.; Souers, A. J. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 2015, 7, 279ra40, 10.1126/scitranslmed.aaa4642
61. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C. S.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C.-M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202-208, 10.1038/nm.3048
62. Salem, A. H.; Agarwal, S. K.; Dunbar, M.; Enschede, S. L.; Humerickhouse, R. A.; Wong, S. L. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma. J. Clin. Pharmacol. 2017, 57, 484-492, 10.1002/jcph.821
63. Choo, E. F.; Boggs, J.; Zhu, C.; Lubach, J. W.; Catron, N. D.; Jenkins, G.; Souers, A. J.; Voorman, R. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab. Dispos. 2014, 42, 207-212, 10.1124/dmd.113.055053